Determining if a Hypersensitivity Reaction is CARPA
CARPA (Complement Activation-Related Pseudoallergy) is diagnosed primarily through clinical presentation and timing, characterized by flushing, myalgias/arthralgias, back pain, and/or chest pressure occurring most frequently at the beginning of infusion—critically, WITHOUT the systemic features of true anaphylaxis (no systemic hypotension, wheezing, peri-orbital edema, respiratory stridor, or gastrointestinal pain). 1
Key Distinguishing Features
Clinical Presentation of CARPA
CARPA reactions are non-IgE-mediated and present with:
- Flushing
- Myalgias and/or arthralgias
- Back pain
- Chest pressure
- Occurs without prior sensitization
- Most frequently at the beginning of infusion
- Self-limited and usually resolves without treatment 1
What CARPA is NOT (True Anaphylaxis Features)
If any of these are present, it is NOT CARPA but rather true anaphylaxis:
- Systemic hypotension
- Wheezing or bronchospasm
- Peri-orbital edema
- Respiratory stridor
- Gastrointestinal pain
- Mucosal swelling
- Airway compromise 1
Diagnostic Algorithm
Step 1: Timing Assessment
- CARPA: Occurs at infusion start, no prior sensitization required
- IgE-mediated allergy: Typically requires prior exposure, occurs within 1-6 hours after last administration 2
Step 2: Symptom Pattern Recognition
If the patient has:
- Cardiopulmonary distress symptoms (flushing, chest pressure, back pain, myalgias) WITHOUT systemic hypotension, airway compromise, or GI symptoms → Suspect CARPA
- Skin/mucosal involvement (urticaria, angioedema) PLUS respiratory compromise OR hypotension → True anaphylaxis 2
Step 3: Drug/Agent Assessment
High-risk agents for CARPA include:
- Liposomal formulations (PEGylated liposomal doxorubicin/Doxil, liposomal amphotericin B) 1, 3, 4, 5
- Nanoparticle-based drug delivery systems
- IV iron formulations (especially those releasing labile free iron) 1
- Taxanes (paclitaxel with Cremophor-EL) 2, 6
Step 4: Laboratory Evaluation
Mast cell tryptase measurement:
- Draw at 1 hour post-reaction (peak time) and compare to baseline
- Elevated tryptase suggests mast cell degranulation (can occur in both IgE-mediated and some non-IgE reactions)
- Normal tryptase does NOT exclude anaphylaxis but makes CARPA more likely if clinical picture fits
- CARPA can occur via basophil or complement activation WITHOUT tryptase elevation 7
Important caveat: Tryptase elevation indicates mast cell degranulation but does not discriminate between allergic and non-allergic mechanisms 7. The rise may be less marked in non-allergic anaphylaxis.
Step 5: Complement Activation Testing (If Available)
- In vitro complement activation assays can detect C3a, C5a generation
- Primarily research tools, not routinely available clinically 8, 9, 10
Management Implications
For CARPA:
- Usually self-limited and resolves without treatment 1
- Slow or temporarily stop infusion
- Symptomatic treatment (antihistamines, corticosteroids if needed)
- Can often restart at slower rate 2
- Premedication with corticosteroids and antihistamines for subsequent infusions 2
For True Anaphylaxis:
- Stop infusion immediately
- Aggressive treatment with epinephrine, fluids, airway management
- Do NOT rechallenge if Grade 3 or higher reaction 2
- Consider desensitization protocols if drug is essential 2
Common Pitfalls
Assuming all infusion reactions are IgE-mediated allergies - CARPA is likely more common than recognized, especially with liposomal and nanoparticle formulations 1, 11
Over-relying on tryptase - Normal tryptase does not exclude anaphylaxis; CARPA can occur via complement/basophil pathways without tryptase elevation 7
Treating CARPA as true anaphylaxis - This leads to unnecessary drug discontinuation when slower infusion rates or premedication would suffice 1
Ignoring the drug formulation - The excipient (Cremophor-EL, polysorbates, liposomal components) may be the culprit, not the active drug 2, 6
Fluid dilution effect - IV fluids given during treatment will dilute tryptase concentrations; account for this when interpreting levels 7